SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Humacyte, Inc. (HUMA) has a negative trailing P/E of -2.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -40.54%, forward earnings yield 58.14%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+511.3%).
- Forward P/E 1.7 — analysts expect a return to profitability with estimated EPS of $0.43 for FY2028.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -40.54% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 58.14% as earnings recover.
- Analyst consensus target $4.50 (+511.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HUMA
Valuation Multiples
P/E (TTM)-2.5
Forward P/E1.7
PEG Ratio0.01
Forward PEG0.01
P/B Ratio32.40
P/S Ratio48.99
EV/EBITDA-1.1
Per Share Data
EPS (TTM)$-0.26
Forward EPS (Est.)$0.43
Book Value / Share$0.02
Revenue / Share$0.01
FCF / Share$-0.67
Yields & Fair Value
Earnings Yield-40.54%
Forward Earnings Yield58.14%
Dividend Yield0.00%
Analyst Target$4.50 (+511.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-2.3 |
0.00 |
1.47 |
31.45 |
- |
| 2020 |
-1.9 |
-0.06 |
1.79 |
84.91 |
- |
| 2021 |
-10.9 |
0.12 |
2.37 |
229.44 |
- |
| 2022 |
-18.2 |
0.22 |
1.86 |
138.94 |
- |
| 2023 |
-2.7 |
0.00 |
21.68 |
0.00 |
- |
| 2024 |
-4.0 |
-0.23 |
-11.36 |
0.00 |
- |
| 2025 |
-3.7 |
0.05 |
48.86 |
74.54 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-4.25 |
$6.19M |
$-85.42M |
-1380.7% |
| 2020 |
$-5.52 |
$1.49M |
$-68.73M |
-4609.4% |
| 2021 |
$0.94 |
$1.26M |
$37.54M |
2972% |
| 2022 |
$0.62 |
$1.57M |
$64.22M |
4103.5% |
| 2023 |
$-1.07 |
$0.00 |
$-110.78M |
- |
| 2024 |
$-1.26 |
$0.00 |
$-148.7M |
- |
| 2025 |
$-0.26 |
$2.04M |
$-40.83M |
-2003.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.44 |
$-0.52 – $-0.39 |
$13.62M |
$13.08M – $14.14M |
4 |
| 2027 |
$-0.20 |
$-0.26 – $-0.17 |
$70.48M |
$52.42M – $88.53M |
3 |
| 2028 |
$0.96 |
$-0.22 – $3.19 |
$308.39M |
$180.35M – $592.63M |
3 |
| 2029 |
$1.85 |
$0.85 – $4.06 |
$520.23M |
$304.24M – $999.73M |
1 |
| 2030 |
$3.56 |
$1.64 – $7.81 |
$935.89M |
$547.33M – $1.8B |
1 |
